- 01Same pool, different trials
ALCAR and L-carnitine end up in the same carnitine pool and use the same transporter into the brain; the real difference is that ALCAR was tested on brain and nerves and L-carnitine on weight, blood sugar and muscle.
- 02Fat-solubility does not predict absorption
Only 14 to 18% of any carnitine supplement is absorbed, and ALCAR is partly turned back into plain carnitine in the gut wall.
A label that says ALCAR holds the same molecule your muscles already store, carrying one extra two-carbon tag. That tag changed where researchers aimed it (the brain and nerves) far more than it changes what reaches your bloodstream, and the evidence behind each bottle is thinner than either label suggests.
ALCAR or L-carnitine: pick by what the trials tested
The carnitine guide covers carnitine itself: what it does, food sources and who runs low. This page answers one narrower question, which of the two forms on the shelf matches which goal.
Read beside this comparison
What is ALCAR, and how is it different from L-carnitine?
Carnitine is a small nutrient your liver and kidneys build from two amino acids, lysine and methionine (more in amino acids explained). About 95% of the body's carnitine sits in heart and skeletal muscle 1. Carnitine's best-known job is the fat shuttle: it carries long-chain fatty acids into the mitochondria, the cell's power units, so they can be burned. Three proteins run that shuttle (CPT1 on the outside, a translocase in the membrane and CPT2 on the inside), and carnitine is the ferry they hand the fat to.
Acetyl-L-carnitine, shortened to ALCAR, is carnitine with an acetyl group attached. An acetyl group is a two-carbon fragment left over from burning sugar and fat. ALCAR is the most abundant carnitine ester the body makes on its own 2. Inside cells, ALCAR can pass its acetyl group to coenzyme A, forming acetyl-CoA, the hub molecule of energy metabolism and the raw material nerve cells use to make acetylcholine, a chemical messenger for memory and muscle control. That link to acetylcholine is why ALCAR ended up in brain trials. A third form, propionyl-L-carnitine (often sold as GPLC, glycine propionyl-L-carnitine), carries a three-carbon group and has a smaller research base, mostly on circulation.
How both forms end up in one carnitine pool
Is ALCAR better absorbed, and does it reach the brain better?
Many labels and guides say ALCAR is more fat-soluble, so it absorbs better and crosses into the brain more easily. The human data do not show that. In Rebouche's review of carnitine kinetics, ALCAR was partly converted back to plain carnitine during absorption, although 2 g a day by mouth still raised blood ALCAR by 43%, so some ALCAR does get through intact 2.
The brain claim rests on even less. In preclinical work on brain-capillary cells, which line the blood-brain barrier, L-carnitine and ALCAR used the same sodium-dependent carrier, a transporter called OCTN2, with near-identical affinity (Km about 33 and 31 µM) 3. Km is the concentration at which a carrier runs at half speed, so two similar Km values mean OCTN2 handles the two forms about equally. No human study shows ALCAR reaching the brain in meaningfully larger amounts than L-carnitine.
What the research shows for each
The table grades each goal by the strength of the human evidence. Limited means some positive trials with real gaps; very low means the reviewers had little confidence in the result; established means standard medical treatment.
| Goal | Form tested | What trials found | Grade |
|---|---|---|---|
| Memory in Alzheimer's or mild impairment | ALCAR | Clinician-rated gain at 12 and 24 weeks, none at 52 weeks or on objective tests 4 | Limited |
| Low mood | ALCAR | Fewer depressive symptoms across 12 trials, with widely varying results 5 | Limited |
| Diabetic nerve pain | ALCAR | Small drop in pain, seen only above 1,500 mg a day 6 | Very low |
| Blood sugar in metabolic conditions | L-carnitine | Modest improvements in glucose markers 1 | Limited |
| Weight loss | L-carnitine | About 1.33 kg more than control, shrinking over time 1 | Limited |
| Exercise recovery | L-carnitine tartrate | Mixed; muscle stores rise only after months | Limited |
| Diagnosed carnitine deficiency | Levocarnitine (prescription) | Standard treatment, managed by a clinician 1 | Established |
Memory and dementia
A Cochrane review pooled 11 ALCAR trials, all in people with Alzheimer's disease. More people on ALCAR were rated improved by their clinicians at 12 and 24 weeks, that effect had gone by 52 weeks, and objective memory and daily-function scores did not differ from placebo 4. The largest single trial followed 431 people with mild to moderate Alzheimer's disease for a year on 3 g of ALCAR a day, and the ALCAR and placebo groups declined at the same rate. A 2003 pooled analysis by Montgomery and colleagues, limited to mild cognitive impairment and mild Alzheimer's disease, found a small advantage for ALCAR (effect size 0.20, which statisticians class as small).
There is no evidence to recommend its routine use in clinical practice.Hudson and Tabet, Cochrane review of acetyl-L-carnitine for dementia 4
For someone noticing slipping memory or fogginess, the brain fog page covers the usual first checks; low B12, thyroid problems and poor sleep explain far more cases of brain fog than low carnitine does.
Mood
A 2018 meta-analysis by Veronese and colleagues pooled 12 randomised trials with 791 people. In the nine trials against placebo or no treatment, ALCAR reduced depressive symptoms with a large average effect (standardised mean difference of -1.10, a measure of effect size where 0.8 or more counts as large) 5. Heterogeneity was very high (I² of 86%), meaning the trials disagreed with each other far more than chance would explain, so the average hides a wide spread. In three trials ALCAR performed about as well as an antidepressant, and the effect looked largest in older adults 5. The authors call for larger trials to confirm or refute the result. Anyone with depression, or already on an antidepressant, is best served by taking the ALCAR question to the prescriber.
Nerve pain in diabetes
The 2019 Cochrane review pooled 4 trials with 907 people who had diabetic neuropathy, nerve damage caused by years of high blood sugar. ALCAR lowered pain by about 9 points on a 100-mm scale at very low certainty, and at 1,500 mg a day or less it did no better than placebo 6. Two placebo-controlled trials reported better vibration sense after 12 months, but gave no numbers the reviewers could check, and two of the four trials were funded by an ALCAR manufacturer 6. People living with type 2 diabetes and burning feet have better-tested options to raise with their clinician first.
Weight, blood sugar and exercise
The weight and metabolism trials used plain L-carnitine or L-carnitine tartrate, not ALCAR. Adults taking L-carnitine lost on average 1.33 kg more than controls in a 2016 meta-analysis, and the gap narrowed the longer the trials ran 1. In people with type 2 diabetes and related metabolic conditions, several trials report modest improvements in fasting glucose markers 1. Muscle carnitine is hard to raise: a 24-week study by Wall and colleagues (Journal of Physiology, 2011) found a 21% rise only when 2 g of L-carnitine tartrate twice a day was taken with 80 g of carbohydrate, enough sugar to trigger the insulin that pulls carnitine into muscle.
Real carnitine deficiency
True carnitine deficiency is a medical diagnosis. Primary carnitine deficiency (a genetic transport defect), dialysis for chronic kidney disease and long-term valproate use can all lower carnitine, and prescription levocarnitine treats it under a clinician's care 1. Vegans have lower blood carnitine than people who eat meat but show no signs of deficiency, because the body still makes enough 1; vegan nutrient deficiencies covers the nutrients that do run short.
Healthy children and adults do not need to consume carnitine from food or supplements, as the liver and kidneys produce sufficient amounts from the amino acids lysine and methionine to meet daily needs.
Which form matches which goal?
The fairest way to choose is to match the form to the goal the trials tested, and to rule out the common causes first. For several everyday goals the honest answer is neither form.
| If the goal is | Form trials used | Realistic expectation | Check first, or instead |
|---|---|---|---|
| Brain fog or memory | ALCAR | Clinician-rated gains for months, none on objective tests 4 | B12, thyroid (TSH), iron, sleep |
| Low mood | ALCAR | Possible benefit; the trials vary widely 5 | A clinician, especially if already on an antidepressant |
| Numb or burning feet with diabetes | ALCAR | Small pain change, only above 1,500 mg a day 6 | B12 and HbA1c |
| Weight loss | L-carnitine | About 1 kg on average 1 | Probably neither; food and activity move far more |
| Gym recovery | L-carnitine tartrate | Mixed; months before muscle stores move | Probably neither for most people |
| Low energy | Neither tested well | No good trials in healthy people | Iron, B12, thyroid, HbA1c |
| Vegan diet | Neither usually needed | The body makes enough 1 | B12 matters far more |
| On dialysis or valproate | Prescription levocarnitine | Clinician-led treatment | Kidney team or neurologist |
| Having chemotherapy | ALCAR discouraged by cancer guidelines (ASCO) 8 | Worse taxane neuropathy in one trial 7 | Oncology team first |
If tiredness is the reason for looking, the fatigue page and supplements for energy cover the causes and the evidence. For memory, supplements for brain health sets out the options with stronger trials behind them.
How much, and how to compare labels
These are the amounts studies used, not a recommendation. ALCAR trials for memory and nerve pain used 1.5 to 3 g a day split into two or three doses 4 6. L-carnitine trials used 1 to 4 g a day, most often 2 g 1. Nausea and a fishy body odour appear at around 3 g a day of either form 1.
Labels make comparison harder because the salt or ester adds weight that is not carnitine. The table shows how much carnitine each common form delivers per gram, worked out from molecular weights.
| Label form | Carnitine per 1 g | Used in |
|---|---|---|
| L-carnitine (base) | About 1 g | Weight and blood sugar trials, prescription levocarnitine |
| L-carnitine L-tartrate (LCLT) | About 0.68 g | Exercise and recovery trials |
| Acetyl-L-carnitine HCl (ALCAR) | About 0.67 g (about 0.85 g as ALCAR) | Memory, mood and nerve pain trials |
| Glycine propionyl-L-carnitine (GPLC) | Varies by product | Small circulation and exercise studies |
Trials gave doses with meals, which eases stomach upset. The advice to take ALCAR in the morning because it keeps people awake comes from user reports, not from trials. Blood carnitine responds within days (the prescription label gives a half-life of 17.4 hours), muscle stores take months, and the ALCAR trials ran for 3 to 12 months before measuring results.
Can you take ALCAR and L-carnitine together?
No trial has tested ALCAR and L-carnitine together. Because both forms end up in the same carnitine pool, the body sees one combined dose, so stomach upset and fishy odour track the total amount of carnitine across both products 1 2. ALCAR is often paired with alpha-lipoic acid for nerve symptoms; each has its own trials in diabetic neuropathy, and the pairing itself has very little direct evidence. Anyone discussing a combination with a clinician can bring the total carnitine per day, worked out from the label form of each product.
Side effects, interactions and who should check first
ALCAR and L-carnitine share the same side effects: nausea, stomach cramps, diarrhoea and a fishy body odour at around 3 g a day 1. The fishy smell comes from trimethylamine, which gut bacteria make from unabsorbed carnitine. The same bacteria produce TMAO (trimethylamine N-oxide), a compound linked to heart disease in observational studies, and whether carnitine supplements raise heart risk through TMAO is still an open question 1.
The documented interactions are specific. The US prescribing label for levocarnitine reports rises in INR, the clotting test used to monitor warfarin, and seizures in people with and without a seizure history. Carnitine blocks thyroid hormone action inside cells: a 2001 randomised trial by Benvenga and colleagues used 2 to 4 g of L-carnitine a day to reverse symptoms of an overactive thyroid, which matters for anyone on levothyroxine or living with hypothyroidism. Valproate and some other seizure medicines lower carnitine levels 1.
Link · DailyMed, US National Library of MedicineLevocarnitine tablets: prescribing informationThe US label for prescription carnitine, with the warfarin and seizure warnings and the 17.4-hour half-life.dailymed.nlm.nih.govCan a blood test show whether you need it?
Carnitine is not on routine blood panels. Plasma free and total carnitine and an acylcarnitine profile are specialist tests, ordered for suspected metabolic disorders, dialysis and long-term valproate use. In practice, the markers that matter more are the ones that rule out other causes or catch an interaction:
- Tingling or burning feet: vitamin B12 and HbA1c (average blood sugar over about three months) or fasting glucose point to the two most common causes.
- Thyroid medicine: TSH and free T4 show whether thyroid hormone is still doing its job once carnitine is in the picture.
- Warfarin: INR is the number carnitine can push up.
- Valproate with confusion or vomiting: ammonia needs checking the same day.
- Kidney function (eGFR): the kidneys reabsorb and regulate carnitine, so kidney disease changes the picture.
Markers to read beside a carnitine question
For how other supplements shift lab numbers, see supplements that affect blood tests.
Free, no accountRead your blood testHave recent bloodwork with B12, HbA1c or TSH on it? Read every line of it, free.Read my results
Citations
- NIH Office of Dietary Supplements. Carnitine: fact sheet for health professionals
- Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004;1033:30-41
- Kido Y, et al. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem. 2001;79(5):959-969
- Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev. 2003;(2):CD003158
- Veronese N, et al. Acetyl-L-carnitine supplementation and the treatment of depressive symptoms: a systematic review and meta-analysis. Psychosom Med. 2018;80(2):154-159
- Rolim LC, et al. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2019;6:CD011265
- Hershman DL, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol. 2013;31(20):2627-2633
- Loprinzi CL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325-3348
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.









